Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

Phase 2

Terminated

Conditions: Hypercatabolic Status Related to Severe Burn

Interventions: Biological: BVS857
Other: placebo

First Posted Date: 2014-03-03

Last Posted Date: 2016-03-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT02074995

Locations: 🇺🇸
Novartis Investigative Site, Winston-Salem, North Carolina, United States

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Phase 3

Completed

Conditions: Chronic Plaque Type Psoriasis

Interventions: Drug: AIN457 300 mg
Drug: ustekinumab 45/90 mg
Drug: placebo secukinumab

First Posted Date: 2014-03-03

Last Posted Date: 2017-07-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 676

Registration Number: NCT02074982

Locations: 🇬🇧
Novartis Investigative Site, Stoke-on-Trent, United Kingdom

Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: QGE031

First Posted Date: 2014-03-03

Last Posted Date: 2017-08-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 270

Registration Number: NCT02075008

Locations: 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom

Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia

Phase 4

Withdrawn

Conditions: Thalassemia (Transfusion Delendent)

Interventions: Drug: deferasirox

First Posted Date: 2014-02-24

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02069886

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Phase 2

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Dexamethasone based mouthwash
Drug: Everolimus
Drug: Exemestane

First Posted Date: 2014-02-21

Last Posted Date: 2017-02-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 92

Registration Number: NCT02069093

Locations: 🇺🇸
Regional Cancer Care Associates Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States
🇺🇸
Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2), Morristown, New Jersey, United States
🇺🇸
Highlands Oncology Group Highlands Oncology Group (22), Fayetteville, Arkansas, United States

and more 20 locations

Urine Sample Collection From FOP Patients

Completed

Conditions: Fibrodysplasia Ossificans Progressiva

First Posted Date: 2014-02-19

Last Posted Date: 2015-03-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT02066324

Locations: 🇺🇸
Novartis Investigative Site, Philadelphia, Pennsylvania, United States

Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients

Phase 3

Terminated

Conditions: Acute Heart Failure (AHF)

Interventions: Drug: Serelaxin
Drug: Standard of Care

First Posted Date: 2014-02-17

Last Posted Date: 2019-03-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2666

Registration Number: NCT02064868

Locations: 🇬🇧
Novartis Investigative Site, Swindon, United Kingdom

Study of Efficacy and Safety of CVAA489 in Hypertensive Patients

Phase 4

Completed

Conditions: Essential Hypertension

Interventions: Drug: amlodipine/valsartan

First Posted Date: 2014-02-14

Last Posted Date: 2017-03-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 115

Registration Number: NCT02062645

Locations: 🇹🇷
Novartis Investigative Site, Talas / Kayseri, Turkey

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Phase 4

Completed

Conditions: Cushing's Disease
Acromegaly

Interventions: Drug: Pasireotide s.c.
Drug: Insulin
Drug: Sitagliptin
Drug: Liraglutide
Drug: Pasireotide LAR
Drug: Metformin

First Posted Date: 2014-02-12

Last Posted Date: 2019-05-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 249

Registration Number: NCT02060383

Locations: 🇺🇸
LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States
🇺🇸
Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States
🇺🇸
East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States

and more 13 locations

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Phase 3

Completed

Conditions: Hereditary Periodic Fevers

Interventions: Drug: Placebo
Drug: Canakinumab

First Posted Date: 2014-02-11

Last Posted Date: 2018-05-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 203

Registration Number: NCT02059291

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy